Cite Filings / STOK / 0001123292-25-000272
Feed Companies Filings Check
Sign in
Cite Filings

Pages

  • Feed
  • Companies
  • Filings
  • Check a claim

Account

  • Sign in
  • Create an account
Support (opens in new tab)
SCHEDULE 13D/A

Beneficial Ownership Report

Stoke Therapeutics, Inc. · Filed 2025-06-06 · Acc 0001123292-25-000272

Documents 1

  • SCHEDULE 13D/A Beneficial Ownership Report , xslSCHEDULE_13D_X01/primary_doc.xml

Around this filing

  • 2025-06-23 SCHEDULE 13D/A Beneficial Ownership Report
  • 2025-06-06 SCHEDULE 13D/A Beneficial Ownership Report
  • 2025-06-06 4 10% owner sold 3,000,000 shares at $10.20 ($30,600,000)
  • 2025-06-06 SCHEDULE 13G Statement of Beneficial Ownership
  • 2025-06-04 8-K Shareholder vote results
  • 2025-06-04 8-K Regulation FD disclosure · Other events
  • 2024-12-27 SCHEDULE 13D/A Beneficial Ownership Report

Link to a passage

At least 12 characters, not counting spaces, so the link points to one passage.

External

  • SEC EDGAR (opens in new tab)

Stakes reported in this filing

Stake history · largest stake in each 13D and 13G

  1. 2026-11-16 SCHEDULE 13G/A · RTW Investments, LP 9.9%
  2. 2026-11-16 SCHEDULE 13G/A · Baker Bros. Advisors LP 4.7%
  3. 2026-11-16 SCHEDULE 13G/A · Wellington Management Group LLP 7.3%
  4. 2026-11-13 SCHEDULE 13G/A · Morgan Stanley 4.9%
  5. 2026-08-12 SCHEDULE 13G/A · The Toronto-Dominion Bank 4.9%
  6. 2026-05-15 SCHEDULE 13G/A · The Toronto-Dominion Bank 5.4%
Loading xslSCHEDULE_13D_X01/primary_doc.xml…

Connection lost

Reconnecting…

Cite Filings isn't responding

Reconnecting…